Skip to content

Study · Measured the body's own peptide · 1990

2 results

Neuropeptide levels in Alzheimer's disease and dementia with frontotemporal degeneration.

Minthon L, Edvinsson L, Ekman R, Gustafson L

Journal of neural transmission. Supplementum1 Jan 1990Cited by 18 (Europe PMC)

PMID1975266 (opens in a new tab)DOI10.1007/978-3-7091-3345-3_6 (opens in a new tab)PepBankPUB-01975266
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Natural levels measured2

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    In patients with dementia of Alzheimer type, cerebrospinal fluid levels of DSIP-like immunoreactivity were reduced.

    In plain wordsIn people with Alzheimer-type dementia, the body's own DSIP levels in spinal fluid were lower.

    Peptide
    Delta sleep-inducing peptide (DSIP)
    Outcome
    DecreaseCSF DSIP-like immunoreactivity
    Study

    n: not reported in source

    Outcome group
    Aging markers · Nervous system and cognition

    Source sentences

    Summary
    The DSIP-LI levels were reduced in DAT
    1 context sentence
    Summary · context
    The CSF levels of somatostatin-LI (SLI), neuropeptide Y (NPY-LI) and Delta Sleep Inducing Peptide (DSIP-LI) have been measured in patients with dementia of Alzheimer type (DAT) and dementia with frontotemporal degeneration of non-Alzheimer type (FTD).

    This result measures the body's own Delta sleep-inducing peptide (DSIP). Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelObservational studyOther

    In patients with dementia with frontotemporal degeneration, cerebrospinal fluid levels of DSIP-like immunoreactivity were slightly increased.

    In plain wordsIn people with frontotemporal dementia, the body's own DSIP levels in spinal fluid were slightly higher.

    Peptide
    Delta sleep-inducing peptide (DSIP)
    Outcome
    IncreaseCSF DSIP-like immunoreactivity
    Study

    n: not reported in source

    Outcome group
    Aging markers · Nervous system and cognition

    Source sentences

    Summary
    slightly increased in FTD.
    1 context sentence
    Summary · context
    The CSF levels of somatostatin-LI (SLI), neuropeptide Y (NPY-LI) and Delta Sleep Inducing Peptide (DSIP-LI) have been measured in patients with dementia of Alzheimer type (DAT) and dementia with frontotemporal degeneration of non-Alzheimer type (FTD).

    This result measures the body's own Delta sleep-inducing peptide (DSIP). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.